“Assisting Iowa companies to expand their highly-specialized research facilities in Iowa is an essential part of our plan to create 200,000 new jobs over the next several years,” said Governor Branstad. “This project adds innovative bioscience job opportunities that help further advance Iowa’s leadership in this critical area of the global economy.”
The project will expand the company’s research capacity with the construction of three specialized vaccine research buildings and fully renovate existing research buildings. As a result of this project, 76 new jobs will be created and 517 jobs will be retained in Iowa.
“The New Research Facility means our Research and Development organization can conduct more studies for the prevention and control of important diseases of livestock and test if our ideas make a difference for the significant unmet medical needs in swine and cattle,” said Dr. Ed Robb, VP of Research and Development at BIVI. “The information we gain from conducting studies in livestock helps set the direction and priority for our research. The facility also assures we have the best husbandry, animal care, record keeping and study designs which assures we can make good decisions about the efficacy and safety of the products under development.”
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
In addition to Governor Branstad, officials from BIVI and the communities of Sioux Center, Ames and Fort Dodge were on hand for the ribbon cutting.